Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Low profitability weakens the company.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 284.33 times its estimated earnings per share for the ongoing year.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The group usually releases earnings worse than estimated.